NorthRock Partners LLC Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN

Key Points

• NorthRock Partners LLC has acquired a new stake in BioMarin Pharmaceutical Inc., purchasing 4,846 shares valued at approximately $266,000.
• Institutional investors own a significant 98.71% of BioMarin's stock, indicating strong institutional interest in the company.
• The stock's average rating is a Moderate Buy, with a consensus target price of $93.26 according to market analysts.

NorthRock Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,846 shares of the biotechnology company's stock, valued at approximately $266,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rise Advisors LLC purchased a new stake in shares of BioMarin Pharmaceutical during the first quarter valued at approximately $30,000. Farther Finance Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock valued at $29,000 after buying an additional 211 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $25,000. Brooklyn Investment Group grew its holdings in shares of BioMarin Pharmaceutical by 2,250.0% during the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company's stock valued at $40,000 after buying an additional 540 shares during the last quarter. Finally, Banque Transatlantique SA purchased a new stake in shares of BioMarin Pharmaceutical during the first quarter valued at approximately $71,000. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Down 0.3%

BMRN opened at $52.95 on Friday. The company has a current ratio of 5.56, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 1-year low of $51.56 and a 1-year high of $73.51. The company has a market capitalization of $10.17 billion, a PE ratio of 15.71, a PEG ratio of 0.67 and a beta of 0.33. The firm's 50 day simple moving average is $55.74 and its two-hundred day simple moving average is $57.67.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. HC Wainwright began coverage on shares of BioMarin Pharmaceutical in a report on Monday, September 8th. They set a "neutral" rating and a $60.00 price target on the stock. Wedbush restated an "outperform" rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Zacks Research cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Raymond James Financial began coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $85.00 target price on the stock. Finally, Wall Street Zen cut shares of BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 11th. Thirteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus target price of $93.26.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.